FDA Grants Clearance to Abiomed’s Launch of their Artificial Lung
Abiomed’s cardiopulmonary bypass system was cleared by the U.S. Food and Drug Administration (FDA) today (10/27) proceeding their April acquisition of Breethe. The effects of COVID-19 have created an increased need for heart recovery in cardiogenic shock patients....
Moderna Inc. Agrees with Qatar Ministry of Public Health for COVID-19 Vaccine Candidate
Today (10/26), Moderna, a top Biopharmaceutical employer, agreed to supply Qatar with their candidate COVID-19 vaccine, which has not yet been approved by any regulatory body. Moderna is currently scaling up their global manufacturing capabilities to be able to...
Europe Runs Low on Pneumonia Vaccine as Demand Grows
With the spike in COVID-19 cases worldwide, there is an increasing amount of people who are seeking precautionary vaccines for respiratory issues in preparation for the winter. Merck’s Pneumovax 23, more specifically, has hit record high sale volumes worldwide in the...
Acute Viral Pneumonia Treatment LungFit Approved by Beyond Air to Enter Clinical Study
In November 2020, the clinical study for treatment of acute viral pneumonia, facilitated by Beyond Air, a medical device and pharmaceutical company, is scheduled to commence. The study will consider enrollment for anyone infected with COVID-19 and pneumonia caused by...
Non-Opioid Pain Management Treatment in Phase One of Clinical Trial
Today (10/20) AmacaThera was granted approval from Health Canada to send their post-operative long-term anesthetic into phase one of clinical trial. This is the first drug they have sent through the clinical trial phase a milestone for the company. AmacaThera was...
At-Home COVID-19 Test Approved by FDA
Today (10/19), the U.S. Food and Drug Administration (FDA) approved Eurofins U.S Clinical Diagnostics at-home COVID-19 test which provides test result within 24 hours and is minimally invasive. This is the first FDA approved self-administered test in circulation from...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com